دورية أكاديمية
The impact of vitamin D on cancer: A mini review.
| العنوان: | The impact of vitamin D on cancer: A mini review. |
|---|---|
| المؤلفون: | Seraphin G; University of Miami, Department of Biology, Coral Gables, FL, USA., Rieger S; University of Miami, Department of Biology, Coral Gables, FL, USA; Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA., Hewison M; University of Birmingham, Institute of Metabolism and Systems Research, Birmingham, UK., Capobianco E; The Jackson Laboratory, Farmington, CT, USA., Lisse TS; University of Miami, Department of Biology, Coral Gables, FL, USA; Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA; iCURA LLC, Malvern, PA, USA. Electronic address: tlisse@icuradx.com. |
| المصدر: | The Journal of steroid biochemistry and molecular biology [J Steroid Biochem Mol Biol] 2023 Jul; Vol. 231, pp. 106308. Date of Electronic Publication: 2023 Apr 11. |
| نوع المنشور: | Review; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: Pergamon Country of Publication: England NLM ID: 9015483 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1220 (Electronic) Linking ISSN: 09600760 NLM ISO Abbreviation: J Steroid Biochem Mol Biol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford ; New York : Pergamon, c1990- |
| مواضيع طبية MeSH: | Neoplasms*/drug therapy , Vitamin D Deficiency*/complications , Vitamin D Deficiency*/drug therapy , Antineoplastic Agents*, Humans ; Vitamin D/metabolism ; Proteomics ; Vitamins/therapeutic use ; Receptors, Calcitriol/metabolism |
| مستخلص: | In this review, we summarize the most recent advances in vitamin D cancer research to provide molecular clarity, as well as its translational trajectory across the cancer landscape. Vitamin D is well known for its role in regulating mineral homeostasis; however, vitamin D deficiency has also been linked to the development and progression of a number of cancer types. Recent epigenomic, transcriptomic, and proteomic studies have revealed novel vitamin D-mediated biological mechanisms that regulate cancer cell self-renewal, differentiation, proliferation, transformation, and death. Tumor microenvironmental studies have also revealed dynamic relationships between the immune system and vitamin D's anti-neoplastic properties. These findings help to explain the large number of population-based studies that show clinicopathological correlations between circulating vitamin D levels and risk of cancer development and death. The majority of evidence suggests that low circulating vitamin D levels are associated with an increased risk of cancers, whereas supplementation alone or in combination with other chemo/immunotherapeutic drugs may improve clinical outcomes even further. These promising results still necessitate further research and development into novel approaches that target vitamin D signaling and metabolic systems to improve cancer outcomes. Competing Interests: Competing interests Authors have nothing to declare. (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.) |
| References: | Proc Natl Acad Sci U S A. 2021 Aug 17;118(33):. (PMID: 34389675) J Bone Miner Res. 2013 Jun;28(6):1478-88. (PMID: 23362149) Front Oncol. 2023 May 09;13:1188641. (PMID: 37228489) Nat Rev Cancer. 2014 May;14(5):342-57. (PMID: 24705652) Am J Cancer Res. 2021 Dec 15;11(12):5951-5964. (PMID: 35018235) JBMR Plus. 2021 Dec 01;6(1):e10572. (PMID: 35079680) Cancer Prev Res (Phila). 2019 Jun;12(6):343-356. (PMID: 31028080) Gene. 2004 Sep 1;338(2):143-56. (PMID: 15315818) Br J Nutr. 2018 Apr;119(8):928-936. (PMID: 29644951) J Diet Suppl. 2022 Nov 14;:1-13. (PMID: 36373265) ACS Appl Mater Interfaces. 2022 Apr 27;14(16):18064-18078. (PMID: 35436103) Melanoma Res. 2023 Apr 1;33(2):126-135. (PMID: 36580363) Endocr Metab Immune Disord Drug Targets. 2021;21(7):1312-1318. (PMID: 32955002) Mol Cell Endocrinol. 2001 May 25;177(1-2):145-59. (PMID: 11377830) Genes Cancer. 2013 Mar;4(3-4):97-104. (PMID: 24020000) Int J Mol Sci. 2021 Nov 25;22(23):. (PMID: 34884550) J Biol Chem. 2009 Feb 6;284(6):3823-32. (PMID: 19075016) Endocrine. 2023 Jul;81(1):168-174. (PMID: 36854857) Front Nutr. 2023 Jan 26;10:1024849. (PMID: 36776613) Int J Mol Sci. 2022 Jan 14;23(2):. (PMID: 35055093) Mol Pharm. 2018 Aug 6;15(8):3216-3226. (PMID: 29902012) Melanoma Res. 2022 Oct 1;32(5):384-387. (PMID: 35979670) Med Sci (Basel). 2020 Mar 13;8(1):. (PMID: 32183076) Eur J Epidemiol. 2023 Jan;38(1):11-29. (PMID: 36593337) J Am Soc Nephrol. 2014 Mar;25(3):564-72. (PMID: 24204002) Neoplasia. 2023 Jan;35:100847. (PMID: 36334333) Expert Rev Anticancer Ther. 2018 Jan;18(1):39-50. (PMID: 29210294) Front Oncol. 2022 May 20;12:839816. (PMID: 35669434) Exp Dermatol. 2019 Jan;28(1):45-52. (PMID: 30372793) Nat Commun. 2020 Feb 21;11(1):1008. (PMID: 32081846) Eur J Immunol. 2007 Feb;37(2):395-405. (PMID: 17274004) Cell Death Dis. 2023 Feb 7;14(2):87. (PMID: 36750554) Int J Clin Exp Pathol. 2013 Oct 15;6(11):2357-65. (PMID: 24228097) Nat Rev Dis Primers. 2020 Nov 26;6(1):92. (PMID: 33243986) Exp Ther Med. 2016 Jun;11(6):2153-2162. (PMID: 27313664) JAMA Netw Open. 2020 Nov 2;3(11):e2025850. (PMID: 33206192) Int J Mol Sci. 2016 Nov 26;17(12):. (PMID: 27898044) J Cancer Res Clin Oncol. 2023 Jan 26;:. (PMID: 36697773) Science. 1997 Sep 19;277(5333):1827-30. (PMID: 9295274) Am J Cancer Res. 2017 Jul 01;7(7):1486-1500. (PMID: 28744399) Prz Gastroenterol. 2019;14(2):89-103. (PMID: 31616522) J Bone Miner Res. 2008 Jul;23(7):974-9. (PMID: 18442312) Curr Med Chem. 2001 Nov;8(13):1661-79. (PMID: 11562285) Curr Colorectal Cancer Rep. 2012 Mar 1;8(1):57-65. (PMID: 23814529) Cell Cycle. 2011 Jun 15;10(12):1888-9. (PMID: 21558808) Endocrinology. 2021 Feb 1;162(2):. (PMID: 33249469) Oncologist. 2020 Sep;25(9):e1406-e1413. (PMID: 32335971) Int J Vitam Nutr Res. 2023 Feb 9;:. (PMID: 36755523) Front Endocrinol (Lausanne). 2019 Nov 14;10:795. (PMID: 31798536) Cancers (Basel). 2022 Apr 29;14(9):. (PMID: 35565359) Front Public Health. 2022 Feb 16;10:811044. (PMID: 35252092) J Steroid Biochem Mol Biol. 2023 Apr;228:106247. (PMID: 36639037) Clin J Am Soc Nephrol. 2008 Sep;3(5):1548-54. (PMID: 18550652) Oncol Rep. 2023 May;49(5):. (PMID: 36928289) Int J Cancer. 2023 Jan 17;:. (PMID: 36650676) Cell Death Dis. 2019 Jan 10;10(1):25. (PMID: 30631035) Support Care Cancer. 2023 Jan 26;31(2):138. (PMID: 36701038) J Steroid Biochem Mol Biol. 2020 May;199:105603. (PMID: 31981799) Endocr Rev. 2008 Oct;29(6):726-76. (PMID: 18694980) Oxid Med Cell Longev. 2023 Feb 16;2023:4772134. (PMID: 36846715) Front Oncol. 2021 Nov 01;11:748061. (PMID: 34790574) J Steroid Biochem Mol Biol. 2023 Mar;227:106234. (PMID: 36572352) J Invest Dermatol. 2023 Feb 20;:. (PMID: 36813159) Curr Drug Targets. 2011 Jan;12(1):4-18. (PMID: 20795941) FASEB J. 2014 Jan;28(1):364-72. (PMID: 24081904) Cancer Lett. 2021 Mar 1;500:1-10. (PMID: 33359211) J Steroid Biochem Mol Biol. 2022 Apr;218:106059. (PMID: 35033661) Int J Mol Sci. 2023 Feb 28;24(5):. (PMID: 36902107) Med Sci Monit Basic Res. 2022 May 05;28:e935139. (PMID: 35642437) Cell Signal. 2023 Mar;103:110577. (PMID: 36567009) SICOT J. 2018;4:12. (PMID: 29629690) J Bone Miner Res. 2013 Jan;28(1):46-55. (PMID: 22886720) PLoS Genet. 2008 Feb;4(2):e7. (PMID: 18248096) Infect Immun. 1973 Apr;7(4):578-85. (PMID: 4128403) Nat Commun. 2020 Jul 30;11(1):3800. (PMID: 32733040) Breast. 2022 Dec;66:15-23. (PMID: 36084384) Cell Commun Signal. 2011 May 08;9:11. (PMID: 21549004) Nutrients. 2022 Dec 06;14(23):. (PMID: 36501221) BMJ. 2019 Aug 12;366:l4673. (PMID: 31405892) Mol Endocrinol. 2014 Oct;28(10):1698-706. (PMID: 25180455) Exp Ther Med. 2011 Mar;2(2):181-193. (PMID: 22977487) Indian J Cancer. 2023 Feb 27;:. (PMID: 36861720) Cancer Res Commun. 2023 Mar 03;3(3):371-382. (PMID: 36875158) Cancer Med. 2021 Jul;10(14):4905-4922. (PMID: 34105887) J Cell Biol. 2009 Apr 20;185(2):203-11. (PMID: 19364925) Crit Rev Eukaryot Gene Expr. 2013;23(3):195-214. (PMID: 23879537) Mol Biol Rep. 2023 Feb;50(2):1385-1391. (PMID: 36469261) Steroids. 2011 Mar;76(4):331-9. (PMID: 21236284) Br J Nutr. 2023 Jan 09;:1-9. (PMID: 36620946) CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525) Mol Pharmacol. 2012 Apr;81(4):498-509. (PMID: 22205755) J Immunol Res. 2019 Apr 10;2019:6384278. (PMID: 31093512) Oncotarget. 2014 Apr 30;5(8):2085-95. (PMID: 24742694) Mol Biol Rep. 2023 Jan;50(1):697-706. (PMID: 36370297) Curr Urol. 2022 Dec;16(4):246-255. (PMID: 36714231) Int J Mol Sci. 2023 Jan 18;24(3):. (PMID: 36768196) J Steroid Biochem Mol Biol. 2015 Apr;148:310-7. (PMID: 25447737) Front Immunol. 2016 Sep 14;7:353. (PMID: 27683579) J Steroid Biochem Mol Biol. 2010 Jul;121(1-2):228-33. (PMID: 20152900) JAMA Oncol. 2023 Apr 1;9(4):546-551. (PMID: 36701139) Med Sci (Basel). 2021 Oct 20;9(4):. (PMID: 34698235) Nucleic Acids Res. 2017 Jan 25;45(2):606-618. (PMID: 27672039) J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):156-62. (PMID: 17113979) Appl Netw Sci. 2022;7(1):1. (PMID: 35013714) Nutrients. 2022 Mar 24;14(7):. (PMID: 35405966) J Cancer. 2018 Apr 30;9(11):2012-2023. (PMID: 29896286) Endocrinology. 2006 Oct;147(10):4801-10. (PMID: 16857747) Int J Med Mushrooms. 2021;23(11):1-15. (PMID: 34936304) Int J Cancer. 2009 Jul 1;125(1):229-34. (PMID: 19330840) World J Oncol. 2023 Feb;14(1):67-74. (PMID: 36895995) Arch Biochem Biophys. 2014 Dec 1;563:94-100. (PMID: 24751483) Phytother Res. 2020 Sep;34(9):2366-2384. (PMID: 32364634) Cancer Treat Res. 2009;152:3-13. (PMID: 20213383) FASEB J. 2011 Mar;25(3):937-47. (PMID: 21123297) N Engl J Med. 2019 Jan 3;380(1):33-44. (PMID: 30415629) Vitam Horm. 2023;121:293-318. (PMID: 36707138) J Womens Health (Larchmt). 2023 May;32(5):561-573. (PMID: 36930144) Endocrinology. 2010 Jun;151(6):2423-32. (PMID: 20392825) |
| معلومات مُعتمدة: | P30 CA034196 United States CA NCI NIH HHS; R01 CA215973 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: Breast cancer; Cancer; Colorectal cancer; EMT; Epithelial to mesenchymal transition; Metastasis; Microenvironment; Osteoblast; Osteosarcoma; Oxidative stress; Prostate cancer; Tumor; VDR; Vitamin D; Vitamin D deficiency; Vitamin D receptor |
| المشرفين على المادة: | 1406-16-2 (Vitamin D) 0 (Vitamins) 0 (Antineoplastic Agents) 0 (Receptors, Calcitriol) |
| تواريخ الأحداث: | Date Created: 20230413 Date Completed: 20230609 Latest Revision: 20240702 |
| رمز التحديث: | 20240702 |
| مُعرف محوري في PubMed: | PMC10330295 |
| DOI: | 10.1016/j.jsbmb.2023.106308 |
| PMID: | 37054849 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1879-1220 |
|---|---|
| DOI: | 10.1016/j.jsbmb.2023.106308 |